This review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (VTE) in patients with lymphoma, multiple myeloma or acute leukemia.
INTRODUCTION
Venous thromboembolism (VTE) is a frequent complication in cancer patients, about five-fold higher than that of the general population, and represents the second cause of morbidity and mortality of this disease. The risk of VTE in cancer is increasing in the latest years, due to improved oncology outcomes, more thrombogenic regimens, and an aging population. VTE risk varies markedly between patients and even within an individual patient over time, reported estimates ranging from 1 to 30% [1] . This is probably due to the large number of factors that act on the VTE risk in a heterogeneous population, such as patients with malignancy. Today, many of the thrombotic risk factors have been identified, including general risk factors (i.e. immobility, age, previous thrombosis history, venous stasis, infections), and risk factors related to cancer (Fig. 1) .
Recent studies show that VTE risk in hematological malignancies is similar to that established in solid tumors at high risk of thrombosis (i.e. pancreatic, ovarian cancer, and brain cancer). This may be masked, however, by the significant impact of other complications like bleeding and infections. Chemotherapy, erythropoietin agents, immunomodulatory drugs, and high-dose steroids also increase the risk of thrombosis in these patients. As compared to noncancer patients, the occurrence of VTE in cancer is more frequently associated with clinical consequences, including recurrent VTE, bleeding, morbidity, requirement for long-term anticoagulant therapy, and an increase in the risk of death. Therefore, in this setting, prophylaxis to prevent VTE is needed. However, in patients with onco-hematological diseases, who are at high risk of thrombocytopenia and hemorrhagic complications, primary and secondary thromboprophylaxis can be complex. Therefore, an accurate estimate of individual patient's VTE risk is clinically very relevant because it allows physicians to target thromboprophylaxis in high-risk individuals. Risk-assessment models incorporating both clinical risk factors and biomarkers have now been validated in multiple
This review summarizes the current knowledge of the epidemiology, prevention, and treatment of VTE, in patients with lymphoma, acute leukemia, or multiple myeloma.
EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN LYMPHOMA
The rate of thrombotic complications in lymphoma is highly variable, ranging from 1.5 up to 59.5% (Fig. 2) [3] [4] [5] [6] [7] 8 && , [9] [10] [11] [12] . Among different lymphoma types, the highest VTE incidence has been observed in patients with primary central nervous system (CNS) lymphoma [3] , a rate frequently observed in tumor of cerebral origin, followed by mediastinal B-cell lymphoma [4, 5] . In a meta-analysis including 18 018 lymphoma patients from 29 independent cohorts, the rate of VTE was 6.4%, being significantly higher in non-Hodgkin lymphoma (NHL, 6.5%) compared with Hodgkin lymphoma (4.7%) patients [6] . Nevertheless, it appears from the different clinical studies that VTE incidence in lymphoma not only depends on tumor subtype and site, but also increases with the stage of disease. A low risk of VTE is described in stage I large B cell lymphoma [7] . Generally VTE risk is higher in high-grade compared with low-grade NHL patients (8.3 vs. 6.3%) [6] . Chemotherapy further increases VTE risk in these patients, mainly in those treated with anthracyclinebased regimens usually requiring central venous device (CVD). A prospective cohort study with Asian population in newly diagnosed lymphoma patients, showed a 7.9% (54/686) overall VTE incidence, particularly 8% in NHL and 6.7% in Hodgkin lymphoma [8 && ]. All VTE events occurred in patients receiving chemotherapy, whereas no VTE were reported in patients without chemotherapy. In this study, VTE was independently associated with
KEY POINTS
Hematologic malignancies (i.e. lymphoma, acute leukemia, and multiple myeloma) are associated with a high risk of thrombotic complications, particularly at the time of diagnosis and during antitumoral treatments.
Thrombotic complications have a significant impact on morbidity and mortality of hematological cancer patients and thromboprophylaxis to prevent venous thromboembolism (VTE) is important. However, no clear recommendation in these conditions is available, with the exception of multiple myeloma.
Large prospective randomized clinical trials are needed to establish the best practice for prevention and treatment of VTE in these types of malignant diseases. age more than 60 years, brain involvement and chemotherapy. Similarly, more than 70% of VTE events were registered before or within the first 3 months of chemotherapy in lymphoma patients [12, 13] . Finally, a poor performance status at diagnosis in patients with diffuse large B-cell lymphoma (DLBCL) was identified as an independent risk factor for VTE, especially early in the course of treatment [5] .
Demographics

EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN MULTIPLE MYELOMA
Multiple myeloma is a clonal plasma cell neoplasm accounting for 15% of hematologic malignancies and 1% of all cancers and its prognosis remains generally poor. The introduction of novel agents, such as the oral immunomodulatory drugs (i.e. thalidomide and lenalidomide) and proteasome inhibitors, has improved the clinical outcome of multiple myeloma [14] . However, a high rate of thrombotic events has been observed when these drugs are given in combination with dexamethasone and/or chemotherapy [15, 16] . Indeed, while the incidence of VTE in multiple myeloma receiving thalidomide alone is 5% or less, it rises to 11.5-26% in newly diagnosed, and to 2-8% in relapsed/refractory patients when thalidomide is given in combination with dexamethasone. VTE incidence can be as high as 58% in regimen containing thalidomide in combination with doxorubicin and dexamethasone [17] . Similarly, a meta-analysis including 3332 multiple myeloma patients [18] showed that patients receiving thalidomide were 2.1 times more likely to have a VTE event compared with those not receiving thalidomide (P < 0.01). Furthermore, those administered thalidomide plus dexamethasone and those administered thalidomide in addition to other chemotherapy agents were 3.1 times more likely and 1.5 times more likely, respectively, to have a VTE event (P < 0.01).
Limited data are available on the incidence of thrombosis with lenalidomide. Clinical studies on the incidence of VTE in relapsed/refractory patients treated with lenalidomide alone have shown a VTE rate of about 3% [19] . However, the combination of lenalidomide plus high-dose dexamethasone, in absence of thromboprophylaxis, increases VTE rate to 6-75% in newly diagnosed and to 4-15% in relapsed multiple myeloma patients [19] [20] [21] [22] . Concomitant therapy with erythropoiesis-stimulating agents increases the incidence of VTE from 5 to 23% in multiple myeloma patients receiving lenalidomide and high-dose dexamethasone [23] . Interestingly, in multiple myeloma patients treated with lenalidomide in combination with bortezomib VTE incidence was less than 2% [24] . It has been suggested that bortezomib possesses an antithrombotic effect by promoting the synthesis of nitric oxide, which results in reduced platelet activation.
In multiple myeloma the occurrence of thrombosis can be associated with significantly poorer survival [25 && ], therefore the prevention of thrombosis in multiple myeloma is an important goal in the management of these patients.
EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN ACUTE LEUKEMIA
As compared to other hematological malignancies, a wide variety of clinical manifestations characterized patients with acute leukemia, ranging from localized venous or arterial thrombosis to diffuse lifethreatening bleeding, secondary to disseminated intravascular coagulation (DIC). Depending on leukemia type [acute myeloid (AML) or acute lymphoid (ALL)] and the associated antitumor treatment, the rate of these complications ranges from 2.1 up to 12.1% (Fig. 3) [26] [27] [28] [29] . A large population-based cohort study in about 8000 patients with acute leukemia, showed a 2-year VTE cumulative incidence of 5.2% in AML and 4.5% in ALL, with the majority of events recorded in the first month of diagnosis [30] . Older age, chronic comorbidities, and CVD were significant predictors of VTE in both acute leukemia types, whereas female sex was a significant predictor in AML, only. The same study found that VTE occurrence was associated with a 40% increase in the risk of dying within 1 year in patients with ALL, but not in those with AML. A particular condition is represented by acute promyelocytic leukemia (APL), in which thrombosis and bleeding manifestations may occur concomitantly as a part of the same thrombo-hemorrhagic syndrome [31 & ]. A role of increased expression of procoagulant activities by APL cells has been implicated in the onset of the severe coagulopathy [32] . In these patients, common abnormalities of routine clotting tests include hypofibrinogenemia, increased circulating levels of fibrinogen-fibrin degradation products, prolonged prothrombin, and thrombin time [33] . The advent of all-trans retinoic acid (ATRA) for induction and maintenance therapy of APL has profoundly modified the outcome of this disease [34] , making APL the most curable leukemia type. Treatment with ATRA rapidly resolves the coagulopathy and improves the hemostatic parameters [32] . However, the rate of early fatal hemorrhages FIGURE 3. Incidence of venous thromboembolism (VTE) evaluated in clinical studies of patients with acute leukemia. Data on VTE rates were grouped according to different type of studies (i.e. retrospective study, prospective study, meta-analysis, and registry data). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; VTE, venous thromboembolism.
remains the most common cause of inductionrelated death in these patients, with rates between 2.4 and 6.5% [35] . Thrombotic complications have been reported in APL, especially during induction therapy, with VTE rate varying, according to the study, from 5.1 to 16% [27, 36, 37] . ALL is associated with increased VTE risk in both adults and children [38] . Depending on the chemotherapy protocols and whether the reported cases are symptomatic or objectively detected, the incidence fluctuates from 1 to 36%. The majority of symptomatic thromboses are CVD-related and involve the upper venous system. In childhood, VTE incidence can vary from 1.1 to 36.7%, with an overall average of 3.2% [26, [38] [39] [40] , and the majority of events occurred during induction therapy with L-asparaginase [40] . In adult ALL, a 5.9% rate of VTE is described during remission induction therapy [41] . CNS thrombosis, involving cerebral venous sinuses, is a distinctive feature of asparaginase-related thrombosis and it occurs in 1-3% of ALL patients [38] . A lower VTE rate was found in adult ALL patients on L-asparaginase who received antithrombin concentrates than in those who did not (4.5 vs. 12.7%, P ¼ 0.04) [42] .
Recently, we described in a group of 84 newly diagnosed ALL children, the variation in some hemostatic markers during chemotherapy [39] . At diagnosis, ALL children presented with laboratory signs of increased thrombin generation and fibrin formation, fibrinolysis inhibition, and endothelial activation and inflammation (Fig. 4) . After starting induction therapy, only thrombin generation markers and inflammatory cytokines significantly decreased. Differently, markers of endothelial activation further increased, particularly during steroid administration, suggesting an insult by chemotherapy on the vascular endothelium.
Stem cell transplantation-associated venous thromboembolism
Thrombotic complications are commonly observed in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) [43, 44] . As described in two retrospective studies [45, 46] , the annual incidence of VTE (including both catheter and noncatheter related events) in 382 autologous hematopoietic stem cell (HSC) and 207 allogeneic-HSC transplanted patients was 3.7%. The incidence of noncatheter associated VTE (1.2%) was significantly increased in allogeneic (2.42%) compared with autologous (0.52%) transplanted patients. At the time of VTE diagnosis the mean platelet count was 121 Â 10 9 l (50-174 Â 10 9 l) and all patients were treated with full dose anticoagulation with low-molecular-weight heparin (LMWH). No significant bleeding complications were observed [46] . In a cohort of 1514 patients undergoing HSCT, incidence of symptomatic VTE was 4.6% (3.6% CVD-related). Differently from the first study, initiation of anticoagulation was associated with an increased risk of bleeding (OR: 3.1, 95% confidence interval, 1.8-5.5) [45] . This difference might be probably related to the different timing of VTE onset. Indeed, in this study the median time to VTE after HSCT was lower (i.e. 64 days) compared with the other study (219 days). Of interest, in both studies the majority of thromboses were catheterrelated.
PROPHYLAXIS AND TREATMENT OF THROMBOSIS IN HEMATOLOGICAL MALIGNANCIES
Prevention of thrombotic complications in hematologic malignancies remains a challenging issue and no studies or guidelines are available to help with best practices for either prevention or treatment of VTE in these diseases. LMWH is usually recommended for prevention and treatment of VTE in cancer patients because of its favorable risk-to-benefit profile. Indeed, compared with vitamin K antagonists (VKA), LMWH is characterized by a reduced need for coagulation monitoring, few major bleeding episodes, and once-daily dosing that make these drugs more suitable in the cancer setting. However, no experience has been built up in patients with acute leukemia, who are characterized by high risk of hemorrhage, related to thrombocytopenia from their primary disease and/or secondary to chemotherapy. An accurate estimate of an individual patient's risk for VTE is therefore clinically very relevant because it allows physicians to target thromboprophylaxis in those who are most at risk for VTE. Risk-prediction models for chemotherapyassociated VTE have become available and include many risk factors, but also begin to incorporate biological markers [2 & ]. Emerging markers are represented by platelet count, leukocyte count, D-dimer, tissue factor (TF), and soluble P-selectin. A VTE risk assessment model for use in patients undergoing chemotherapy has been published by Khorana et al. [47] , based on five predictive variables in cancer patients (i.e. cancer site, platelet count, hemoglobin level or the use of erythropoiesisstimulating agents, leukocyte count, and BMI). This model uses a simple scoring system, is based on readily accessible baseline clinical and laboratory data, and has been shown to accurately predict the short-term risk of symptomatic VTE in patients undergoing chemotherapy-based treatments. More recently, Ay et al. [48] expanded Khorana's model by adding P-selectin and D-dimer quantification. This allowed a better stratification of the thrombotic risk.
Targeted thromboprophylaxis utilizing modelbased and/or biomarker-based approaches may provide an optimal risk-benefit ratio. In this context, emerges the important role of circulating microparticles, submicrometric membrane fragments that circulate in the blood bringing on their surface TF and procoagulant phospholipids. A recent study, performed in patients with essential thrombocythemia, demonstrated the presence of increased levels of circulating microparticles of platelet and endothelial cell origin, which was more prominent in those patients with more risk factors for thrombosis [49] . High microparticles have been also detected in patients with acute leukemias or multiple myeloma [50, 51] .
PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
Current guidelines cover only a little part of onco-hematologic patients. Some information on thromboprophylaxis in patients with acute leukemia and lymphoma come from two studies [52, 53] . A prospective Italian observational study evaluated the incidence of CVD-related thrombosis in patients with exclusively hematologic malignancies (CATHEM). Among the 416 enrolled patients, 14.2% were receiving thromboprophylaxis, mostly LMWH, but also unfractionated heparin, aspirin (ASA), or warfarin [53] . In these patients no increase in hemorrhagic complications was observed. The randomized controlled clinical trial (RCT) by Couban et al. [52] evaluated the role of 1 mg fixeddose warfarin in preventing CVD-related thrombosis; about 80% of enrolled patients had hematologic malignancies. This prophylactic strategy was not effective in reducing VTE rate, but no differences with placebo were observed with regard to bleeding complications.
More data on thromboprophylaxis are available in multiple myeloma [16] . Given the high-VTE risk when these patients are treated with thalidomide or lenalidomide in combination with dexamethasone or multiagent chemotherapy, thromboprophylaxis is recommended. However, which agent is the most appropriate is a matter of debate. Recently ,   T0  T1  T2  T3   T0  T1  T2  T3  T0  T1  T2  T3   T0  T1  T2 
TREATMENT OF VENOUS THROMBOEMBOLISM
The standard treatment regimen for a first acute VTE episode consists of an initial therapy with heparins (either UFH, LMWH or fondaparinux), followed by long-term therapy with a VKA agent for 3-6 months. LMWH is at least as efficacious as UFH in reducing recurrent thrombosis and is associated with a lower risk of major bleeding. Today, monotherapy with LMWH for at least 6 months is recommended for an established VTE event in the cancer patient, due to its safety profile, no need for laboratory monitoring, and less variability (compared with warfarin) due to interference from drug and food [56, 60] .
A very limited experience exists in patients with hematologic malignancies and VTE [61, 62] . Patients with hematologic malignancies are also at high risk for hemorrhages, and some recommendations for the standardization of dose-reduction regimens and guidelines for temporary suspensions of the LMWH according to the degree of thrombocytopenia have been recently provided by an expert panel [63] . LMWH should be reduced if thrombocytopenia occurs: a 50% reduction may be performed with platelet count below 50 000 per ml, and a temporarily discontinuation of LMWH for platelet count below 20 000 per ml.
Treatment of the acute promyelocytic leukemia coagulopathy
The more recent recommendations indicate that three simultaneous actions must be immediately undertaken when a diagnosis of APL is suspected: start of ATRA therapy; administration of supportive care with plasma and platelet transfusions; confirmation of molecular diagnosis [31 & , [64] [65] [66] . The role of heparin in the treatment of the coagulopathy remains uncertain. In a retrospective analysis of 268 patients [34] , no benefit from unfractionated heparin was observed with respect to early hemorrhagic deaths, complete remission rate, or overall survival. No systematic studies have been reported on the use of LMWH or any of the newer anticoagulants (i.e. factor Xa and IIa inhibitors, hirudin, fondaparinux) to treat the thrombo-hemorrhagic syndrome of APL. The use of antifibrinolytic agents (i.e. epsilon-aminocaproic acid and tranexamic acid) or protease inhibitors (i.e. aprotinin) has been suggested, but no data from RCT have been published. An increase of thromboembolic events occurred when antifibrinolytic agents were administered in conjunction with ATRA. A lack of efficacy of tranexamic acid prophylaxis on the hemorrhageassociated mortality in APL was shown by the large PETHEMA trial [35] .
Current recommendations suggest platelet transfusion prophylaxis as an essential part of supportive care for APL, in order to maintain platelet count above 20x10 9 per l in patients not actively bleeding and above 50x10 9 per l in those with active bleeding [33, 67] . The use of ATRA for remission induction has helped to resolve the coagulopathy, however, the rate of very early hemorrhagic deaths is still significant (3-10%). Additional efforts to develop therapies that rapidly correct the coagulopathy are required. RCT of different prophylactic regimens to prevent hemorrhage and/or thrombosis are needed, particularly in patients with APL [63] .
CONCLUSION
Patients with lymphomas, multiple myeloma, and acute leukemia have an increased thrombotic risk, particularly at the time of diagnosis and during chemotherapy treatments with L-asparaginase, or antiangiogenic drugs. Thrombotic complications have a significant impact on morbidity and mortality of these patients, and thromboprophylaxis to prevent VTE is required. However, anticoagulant therapy is very complicated in hematologic cancer patients, who are at very high hemorrhagic risk, and no definite guidelines for VTE management are available. Also the role of new anticoagulant is yet unknown.
